Human HLA-A*03:01&B2M&KRAS G12V (VVVGAVGVGK) Tetramer Protein (MHC-HM418T)
Catalog: MHC-HM418T
Order now get it on
| Product Description | Recombinant Human HLA-A*03:01&B2M&KRAS G12V (VVVGAVGVGK) Tetramer Protein is expressed from HEK293 with His tag and Avi tag at the C-Terminus, tetramer is assembled by biotinylated monomer and streptavidin.It contains Gly25-Thr305(HLA-A*03:01),Ile21-Met119(B2M) and VVVGAVGVGK peptide. |
Product Background |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. |
Product Category |
Recombinant Protein |
Target |
KRAS G12V (HLA-A*03:01) |
| Synonyms | MHC; KRAS; K-Ras 2; KRAS2; C-K-RAS; CFC2; K-RAS2A; K-RAS2B; K-RAS4A; K-RAS4B; KRAS1; KRAS2; NS; NS3; RASK2; GTPase Kras; KI-RAS; RALD |
| MHC Form | Tetramer |
| Allele | HLA-A*03:01 |
Gene/Protein ID |
NP_002107.3(HLA-A*03:01)&P61769(B2M)&VVVGAVGVGK |
Species |
Human |
Exact Sequence |
Gly25-Thr305(HLA-A*03:01),Ile21-Met119(B2M)and VVVGAVGVGK peptide |
| Molecular Weight | The protein has a predicted MW of 258 kDa. Due to glycosylation, the protein migrates to 260-265 kDa under Non reducing (N) condition based on Tris-Bis PAGE result. |
Activity |
Immobilized Human HLA-A*03:01&B2M&KRAS G12V (VVVGAVGVGK) Tetramer, His Tag at 5ug/ml (100ul/Well) on the plate. Dose response curve for Anti-HLA-A*03:01&B2M&KRAS G12V (VVVGAVGVGK) Antibody, hFc Tag with the EC50 of 0.18ug/ml determined by ELISA (QC Test). The affinity constant of 42.3 nM as determined in SPR assay (Biacore T200). See testing image for detail. |
Product Tag |
C-His-Avi |
Express System |
HEK293 |
| Purity | > 95% as determined by Tris-Bis PAGE;> 95% as determined by HPLC |
| Endotoxin | Less than 1EU per ug by the LAL method. |
| Form | Lyophilized |
| Shipping | Shipped at ambient temperature. |
| Formulation | Lyophilized from 0.22um filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization. |
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 ug/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Stability And Storage | Reconstituted protein stable at -80°C for 12 months, 4°C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. |
|
|
Anti-HLA-A*03:01&B2M&KRAS G12V (VVVGAVGVGK) Antibody captured on CM5 Chip via Protein A can bind Human HLA-A*03:01&B2M&KRAS G12V (VVVGAVGVGK) Tetramer, His Tag with an affinity constant of 42.3 nM as determined in SPR assay (Biacore T200). |
|
|
Immobilized Human HLA-A*03:01&B2M&KRAS G12V (VVVGAVGVGK) Tetramer, His Tag at 5ug/ml (100ul/Well) on the plate. Dose response curve for Anti-HLA-A*03:01&B2M&KRAS G12V (VVVGAVGVGK) Antibody, hFc Tag with the EC50 of 0.18ug/ml determined by ELISA (QC Test). |
|
|
The purity of Human HLA-A*03:01&B2M&KRAS G12V (VVVGAVGVGK) Tetramer is greater than 95% as determined by SEC-HPLC. |
|
|
Human HLA-A*03:01&B2M&KRAS G12V (VVVGAVGVGK) Tetramer on Tris-Bis PAGE under Non reducing (N) condition. The purity is greater than 95%. |
You may also be interested in
View more associated products